SPP1 facilitated cancer cell chemoresistance via the activation of the CD44 receptor, PI3K/AKT signaling, and ATP-binding cassette (ABC) drug efflux transporter activity, and anti-SPP1 and anti-CD44 antibodies improved the sensitivity of cancer cells to cisplatin in a mouse model [74]. This evidence concerns the gene SPP1 and cancer.